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Abstract
Sik1 (salt inducible kinase 1) is a serine/threonine kinase that belongs to the stress- and energy-sensing AMP-activated
protein kinase family. During murine embryogenesis, sik1 marks the monolayer of future myocardial cells that will populate
first the primitive ventricle, and later the primitive atrium suggesting its involvement in cardiac cell differentiation and/or
heart development. Despite that observation, the involvement of sik1 in cardiac differentiation is still unknown. We
examined the sik1 function during cardiomyocyte differentiation using the ES-derived embryoid bodies. We produced a null
embryonic stem cell using a gene-trap cell line carrying an insertion in the sik1 locus. In absence of the sik1 protein, the
temporal appearance of cardiomyocytes is delayed. Expression profile analysis revealed sik1 as part of a genetic network
that controls the cell cycle, where the cyclin-dependent kinase inhibitor p57
Kip2 is directly involved. Collectively, we
provided evidence that sik1-mediated effects are specific for cardiomyogenesis regulating cardiomyoblast cell cycle exit
toward terminal differentiation.
Citation: Romito A, Lonardo E, Roma G, Minchiotti G, Ballabio A, et al. (2010) Lack of Sik1 in Mouse Embryonic Stem Cells Impairs Cardiomyogenesis by Down-
Regulating the Cyclin-Dependent Kinase Inhibitor p57
kip2. PLoS ONE 5(2): e9029. doi:10.1371/journal.pone.0009029
Editor: Rory Edward Morty, University of Giessen Lung Center, Germany
Received April 20, 2009; Accepted January 11, 2010; Published February 3, 2010
Copyright:  2010 Romito et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Project was supported by the grant from 6th Framework of EU Commission, Contract no.: 037627 to A.B., A.R. and G.C. and the Italian Association for
Cancer Research (AIRC) and Telethon Foundation grant to G.M. and E.L. The funders had no role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: cobellis@tigem.it
Introduction
The formation of the heart involves a precisely orchestrated
series of molecular and morphogenetic events, and even a subtle
perturbation of this process can have catastrophic consequences
for cardiac function. The specification of the appropriate
n u m b e r sa n dt y p e so fc a r d i a cc e l l si sa ne a r l ye v e n td u r i n g
embryogenesis. These cells then migrate to form a simple, yet
functional, heart tube. Further morphogenesis transforms this
heart tube into morphologically and functionally discrete cardiac
chambers [1].
Cardiomyogenesis depends on the regulated activities of
numerous specific transcription factor genes, which encode
members of the zinc finger [2], homeodomain [3], T-box [4],
bHLH [5] and MADS domain families [6]. These factors act in a
combinatorial way to create a positive feed-forward regulatory
circuitry that controls the development of cardiac myocytes. A
concomitant regulation in the expression and activities of cell-
cycle regulatory molecules (cyclins, cyclin-dependent kinases
and cyclin-dependent kinase inhibitors [CDKIs]) is essential for
the control of cell proliferation that is concurrent with
differentiation [7]. Among multiple cell-cycle regulators, CDKI
p57
Kip2 is the first to be detectable in the developing heart, at
E10.5, and is involved in cardiac cell-cycle exit during chamber
maturation [8].
The sik1 protein was identified in a screen for kinases specifically
expressed in the heart of the mouse embryo [9]. During mouse
embryogenesis, sik1 expression is detected at 8.0 d.p.c. in the
monolayer of the future myocardial cells; it is rapidly down-
regulated at 8.5 d.p.c. upon formation of the primitive ventricle,
although it is still present in the myocardial cells that will populate
the primitive atrium and bulbus cordis. At 9.5 d.p.c. sik1 expression
is down-regulated in the primitive atrium but still detected in the
sinus venosus and truncus arteriosus. The expression pattern of sik1
gene suggests a role during the earliest stages of myocardial cell
differentiation and/or primitive chamber formation [10]. Recent
studies have demonstrated that sik1 protein phosphorylates class II
HDACs in vivo, triggering thecytoplasmic exportof the HDACs and
activation of MEF2-dependent transcription [11,12].
The specific expression pattern of sik1 during mouse develop-
ment prompted us to investigate the role of sik1 in the regulation
of cardiac lineage commitment in a stem-cell model system.
Embryonic stem (ES) cells can differentiate into derivatives of all
three of the primary germ-cell layers, including cardiomyocytes,
and previous studies have suggested that early steps in
embryonic cardiomyogenesis take place during embryoid body
(EB) differentiation of ES cells [13]. Using an ES cell line
carrying a gene-trap insertion in the sik1 gene, we produced a
sik1-deficient cell line. The cardiac developmental program in
the ES cell/EB model is affected in the absence of sik1. The
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flp/flp
EBs and analysis of cardiac markers revealed a down-regulation of
terminal cardiac markers (aMyHC, Mlc2v, aCach and cTnI). When
analyzed in depth, these cells showed a significant delay in cardiac
differentiation in the absence of sik1, due to a defect in cell cycle exit
of differentiating cardiomyoblasts. Gene profiling studies were
performed to identify genes that may play a role in regulating sik
specific function. One of the most down-regulated genes with
cardiac expression was cdkn1c codifying for p57
Kip2, a cyclin-
dependent kinase inhibitor (CDKI), which showed a peculiar
transcriptional regulation during cardiac differentiation, lost in the
absence of sik1.
Forced expression of p57
Kip2 in sik1-deficient ESCs was able to
rescue the mutant phenotype.
Our data thus indicate that sik1 via p57
Kip2 might have a central
role in the control of the exit of cardiomyoblasts from the cell cycle
toward the terminal differentiation of cardiomyocytes.
Results
Generation of sik1
flp/flp ES Cell Clone
To study the role of the sik1 gene during cardiomyocyte
differentiation, we used a gene-trap ES cell line (GC389) (http://
genetrap.tigem.it/public) [14] carrying a pFlipa1 vector insertion,
as shown in figure 1. The fusion transcript generated by the gene-
trap vector insertion directs the expression of a truncated protein
carrying only the N-terminal domain of SIK1 (residues 1 to 249)
fused to the b-geo cassette (Fig. 1A).
We mutated the second allele of sik1 by cultivating heterozygous
mutant cells (sik1
wt/flp) in increasing concentrations of the neomycin
analogue G418, as previously described [15]. Several independent
surviving clones were isolated and analyzed by RT-PCR to
discriminate cells that were homozygous for the trapped allele
(sik1
flp/flp)o v e rsik1
wt/flp cells. Clones carrying the gene trap insertion
on both alleles that did not express the wild-type transcript anymore
Figure 1. Effects of gene trapping insertion and screening of homozygous mutant ES cells. (A) Schematic representation of the sik1 gene
encoding for a protein of 779 amino acids. The SIK1 protein structure is visualized: the kinase domain (27 to 278), the UBA motif (303–343), the PKA
motif (567–584) and the nuclear localization signal (586 to 612). The insertion of the gene-trap vector occurred in the seventh intron of the wild-type
sik1 gene, causing a deletion of the protein segment from residue 250 to 779. The corresponding fusion transcript and the resulting protein are
depicted. (B) Identification of homozygous ES clones for the trapped allele with RT-PCR analysis. Schematic representation of the oligonucleotides
used to discriminate between the wild-type and fusion transcripts. X, Y and Z correspond to primers sik1UP, sik1LW and L232, respectively. The
amplification of wild-type and mutant cDNA results in two products of different molecular weight, 682 bp and 378 bp respectively. Lanes: 1,2 and 3,
amplification of sik1
wt/wt cDNA; 4,5 and 6, amplification of sik1
wt/flp cDNA; 7,8 and 9 amplification of sik1
flp/flp cDNA; 10, sik1
wt/wt total RNA; 11 and 12,
sik1
wt/flp total RNA; 13, sik1
flp/flp total RNA. The arrow indicates the 500-bp band of the DNA molecular weight marker. The arrow indicates the 500-bp
band of the DNA molecular weight marker. (C) Western blot on proteins extracted from wild-type and sik1
flp/flp ES cells using an antibody against the
b-galactosidase. In sik1
flp/flpES cells is possible to detect a band corresponding to the fusion protein that is absent in wild-type ES cells. Different
amounts of proteins were used on western blot. (D) Expression plasmids (6 mg) for FLAG-tagged sik1 and its truncated version (1–249aa) were
transfected into HEK293T cells and subjected to immunoprecipitation with FLAG-M2 resin. Aliquots of FLAG-SIK1 wt and truncated IPs were
subjected to western blotting (WB) using an anti-FLAG antibody (left panel) and to in vitro kinase assays using [c-
32P]- ATP with AMARA peptide as a
substrate (right panel). The relative activation was calculated by subtracting counts incorporated in the assay of non-immune sample from gross
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protein in sik1
flp/flp ES cells was confirmed by western blot analysis
using an antibody against the b-galactosidase (Fig. 1C). Moreover,
enzyme activity, determined as the ability of truncated sik1 to
phosphorylate the specific AMARA peptide substrate in comparison
to the full-length protein, was measured. To this end, FLAG-tagged
sik1 (1–249) and full-length protein were expressed in HEK293 cells
and,afterimmunoprecipitation,thepeptide phosphorylationactivity
was measured using radio-labeled ATP. As expected, the full-length
sik1 was able to efficiently phosphorylate the AMARA substrate;
whereas the phosphorylation signal of the mutant protein was
dramatically reduced, indicating that the catalytic activity of the
truncated sik1 is almost inactive (Fig. 1D). We then evaluated the
subcellular localization of the truncated form of sik1 (residues 1 to
249) produced by the trapped allele. It is known that the wild-type
protein is resident in the nucleus where it exerts its function [16]. In
contrast, the cells expressing the truncated form of sik1 showed an
intense signal only in the cytoplasmic compartment, as opposed to
the full-length protein that was mainly located in the nucleus
(Fig. 1E). The gene-trap insertion resulted in the deletion of the
nuclear localization signal; therefore, as expected, this truncated
version of the sik1 protein showed a different localization compared
to the full-length sik1.
Altogether, these data indicate that the gene-trap insertion
interrupts sik1 expression and results in the production of an
inactive protein with a cytoplasmic localization.
Delayed Cardiomyocyte Differentiation in sik1
flp/flp ES
Cells
The next step was to evaluate the developmental potential of
sik1
flp/flp ES cells to differentiate in cardiomyocytes compared to
wild-type and sik1
+/flp cells using the ‘‘hanging drop’’ method. The
embryoid bodies (EBs) generated clusters of adherent cells that
began to contract rhythmically, indicating differentiation to the
cardiac lineage, a derivative of the mesoderm layer. Seventy-six
percent of plated EBs derived from wild-type ES cells showed
areas of contracting cardiomyocytes starting from the day after
adhesion (day 6, Fig. 2A). The appearance of beating EBs
increased and reached over 92% at day 8 of culture. In contrast,
EBs derived from sik1
flp/flp cells showed a dramatic reduction in the
formation of contractile areas (5% at day 6). However, a gradual
increase of beating EBs was seen in the following 4 days of culture,
Figure 2. In vitro differentiation and proliferation potential of sik1
flp/flp ES cells. (A) Percentages of EBs differentiating to beating
cardiomyocytes. EBs derived from wild-type, sik1
wt/flp, sik1
flp/flp and sik1
flp/flp+HA-sik1 ES cells were used to monitor differentiation into
cardiomyocytes. Sik1
flp/flp + HAsik1 used corresponds to HAsik1 B6 clone expressing the highest level of sik1 (B). Three independent experiments
were performed, each plating an equal number of EBs (n=120). The statistical significance of the observed differences between the percentage of
wild-type and mutant beating EBs were analyzed and the time points in which major differences were observed (days 6 and 7) showed significant p-
values of 1.109e
208 and 3.271e
208, respectively. P-values were calculated using a two-sample test for equality of proportions with continuity
correction. (B) RT- and Q-PCR analysis on wild-type ES cells and three representative clones carrying the HA-sik1 transgene. Data represent fold
change of transgene expression vs. sik1 endogenous level. (C) Proliferation assay measured by BrdU incorporation. (D). Cell-cycle distribution of the
wild-type and sik1
flp/flp populations by FACS analysis.
doi:10.1371/journal.pone.0009029.g002
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flp/flp EBs reached the same percentage of beating
EBs as wild-type cells (Fig. 2A). The EBs derived from sik1
+/flp cells
showed an intermediate phenotype compared to sik1
flp/flp EBs,
which can be attributed to a gene-dosage effect.
We then tested whether functional rescue of cardiomyocyte
differentiation can be achieved by gene re-introduction. To this
purpose, we generated stable clones overexpressing the HA-tagged
sik1 transgene. Several drug-resistant clones were amplified and
RNA extracted to measure the expression of HA-sik1 by qPCR.
Sik1 transgene expression was detected in all clones analyzed;
however, none of them reached the basal level of endogenous sik1
expression (Fig. 2B). The clone B6, which showed the highest level of
transgene expression, was induced to differentiate into cardiomy-
ocytes. The HA-sik1(B6) overexpressing clone only partially
restored the appearance of the beating cardiomyocytes (Fig. 2A).
Since over-expression experiments do not allow the modulation of
kinase activity both in terms of timing and signal strength and,
moreover, since the levels of transgene expression in selected
clones were lower than in the heterozygous cells, the combination
of these drawbacks might explain the incomplete rescue (Fig. 2A).
Taken together, these data indicate that the sik1
flp/flp population
can differentiate into contracting cardiomyocytes, but showing a
consistent delay in cardiomyogenesis.
Having shown that lack of sik1 led to a delayed differentiation,
we assessed the proliferative potential of sik1
flp/flp ES cells by BrdU
incorporation, postulating that the lack of sik1 might increase the
proliferation rate of these cells. In line with this hypothesis, the rate
of sik1
flp/flp cell proliferation significantly increased (15%)
compared to the wild-type cells (Fig. 2C). These data were also
confirmed by cell counting (data not shown). The increased
proliferation rate of sik1
flp/flp ES cells resulted from a shortened G1
phase (wt 37% vs. sik1
flp/flp 23%, Fig. 2D) and accumulation in S-
phase, (wt 55% vs. sik1
flp/flp 72%, Fig. 2D).
sik1 Deficiency Specifically Affects Cardiac Differentiation
of ES Cells
We evaluated the expression of pluripotency genes as well as of
mesoderm induction and specification markers. We measured the
expression of Oct-3/4 transcript, a pluripotency marker, and
Brachyury transcript, which is required for correct mesoderm
formation and patterning [17]. As shown in figure 3A, sik1
deficiency did not affect Oct-3/4 expression, which was progres-
sively downregulated in both cell populations, nor Brachyury, which
was nearly absent in the undifferentiated ES cells and transiently
expressed during embryoid body formation peaking at day 4. At
the same time, committed mesodermal cells started to express
similar levels of pre-cardiac mesodermal genes (Mesp1, Mesp2 and
Islet-1 [18] in both the wild-type and in the sik1
flp/flp differentiating
populations.
Given the delay in cardiomyogenesis (Fig. 2A), we studied
cardiac differentiation in sik1
flp/flp differentiating EBs measuring
the levels of cardiogenic transcription factors (Nkx2.5, Tbx5 and
Mef2C), which are first expressed in cardiomyoblast cells [19].
These factors then act in combination to activate the expression of
several cardiac structural genes, i.e. myosin heavy chain (a-MyHC),
myosin light chain (Mlc2V), calcium channel (aCach) and cardiac
troponin (cTnI) [20]. We measured the expression of these genes
both in the wild-type and in the sik1
flp/flp differentiating EBs.
Nkx2.5, Tbx5 and Mef2C expression started at day 5 in the wild-
type EBs and progressively increased. In the sik1
flp/flp differenti-
ating EBs, the expression of these genes was impaired in this time
window; in line with the morphological analysis, the expression of
the cardiac structural genes (a-MyHC, Mlc2V, aCach and cTnI) was
impaired from day 6 to day 8, whereas it increased from day 9
onward to reach levels comparable to wt cells. (Fig. 3A),
Next, we also examined the influence of sik1 on the induction of
the hematopoietic/endothelial lineage, measuring the expression
of Runx1, VegfC and Flk1. As shown in figure 3B, the levels of
expression of these genes were not significantly impaired in the
sik1
flp/flp differentiating population.
Altogether, these data suggested that mesoderm formation and
patterning were not altered ab inicio, as demonstrated by the
correct expression of Mesp1, Mesp2 and Isl1, but the cardiogenic
programme of these cells was delayed, as showed by the
downregulation of Nkx2.5, Tbx5 and Mef2C genes as well as of
markers of terminal cardiac differentiation (aMyHC, Mlc2v, aCach,
cTnI).
In order to ascertain whether lack of sik1 affected the number of
cardiac cells, we quantified the percentage of cardiomyocytes
derived from wild-type and sik1
flp/flp EBs throughout the
differentiation by FACS analysis. To this end, we used the
sarcomeric myosin (MF-20) staining (Fig. 4A, 4B). In line with our
hypothesis, from day 5 to day 7, the sik1
flp/flp -derived EBs showed
a reduced number of MF-20 positive cells, compared to the wt
EBs. However, at day 9, the number of cardiomyocytes was fully
rescued in the sik1
flp/flp EBs, according to the morphological and
qPCR analysis reported above (Fig. 2A–3A).
Furthermore, we analyzed the FACS data by discriminating
high fluorescence (hf) vs. low fluorescence (lf) cells expressing
sarcomeric myosin (MF-20). Remarkably, while a significant
number of hf cells already appeared at d5 in wt EBs and the hf
vs. lf ratio was comparable throughout the differentiation, in
sik1
flp/flp EBs, consistent number of hf cells can be detected only
starting from day 9 onward (Fig. 4C).
All together, these data supported the idea that the appearance
of cardiomyocytes in sik1
flp/flp EBs occurred as a slower wave of
differentiation.
Worth noting, in many cell types the differentiation is strictly
dependent on the cell cycle withdrawal. We thus reasoned that the
difference observed in the two cell populations may be due to a
defect of the mechanism that regulates cell cycle exit toward
differentiation of cardiomyocytes. To directly address this issue, we
carried out FACS analysis to study the concurrent cell cycle
withdrawal and differentiation in the cardiomyocyte population in
both groups and in the most critical days of differentiation (d5–d7).
To this end, we performed double immunostaining studies using
an antibody against a cardiac sarcomeric protein (cTnI) coupled
with the analysis of cell cycle activity (BrdU). On day 5, double
positive cells dramatically increased in sik1
flp/flp vs. wt population,
indicating that cell cycle exit of cardiomyocytes was impaired in
absence of sik1 (Fig. 4C). Furthermore, at day 6, few double-
positive cells were detected in the wt population, which almost
disappeared at day 7. On the contrary, in the sik1
flp/flp population,
the MF20/BrdU-positive cells decreased in number at day 6 but
were still present at day 7, supporting the idea of a delayed cell
cycle withdrawal in absence of sik1.
Lack of sik1 Does Not Affect Neuronal Differentiation
In order to exclude a general effect of sik1 deficiency on ESC
differentiation, we evaluated whether sik1 deficiency impairs
neuronal differentiation. As shown in figure 5A, both the wild-
type and the sik1
flp/flp EBs were able to generate a dense network of
neurite growth [21]. The neural nature of these cells was
confirmed by staining with an antibody against the neuron-
specific form of class bIII-tubulin (Fig. 5A). We also measured the
expression of the neuron- and glia-specific markers NFM and
GFAP (Fig. 5B). The expression of NFM and GFAP was similar in
Sik1 Controls Cardiomyogenesis
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flp/flp populations, thus indicating that the
EBs carrying the sik1 mutant alleles have the same competence to
acquire the neural phenotype as the wild-type EBs; supporting the
idea of a cardiac specific effect of sik1 deficiency.
The p57
Kip2 Transcript Is Strongly Downregulated in
sik1
flp/flp ES Cells
Giventheroleofsik1astranscriptionregulator [12], we studiedthe
transcriptomeinfluenceofsik1inEScells.Wedecidedtoperformthe
experiment on undifferentiated ES cells, comparing wild-type and
sik1
flp/flp cells, for three reasons: 1. to consider a homogenous cell
population compared to differentiating EBs, which are known to
contain different cell types; 2. to avoid an enrichment of cardiac
specific genes, already found to be significantly altered in the previous
analysis, and 3. to possibly reveal an early transcriptional event that
mayplayaroleinembryonicdevelopment.Usingthefilteringcriteria
of a two-or-greater-fold change in expression and a false discovery
rate of less than 5%, 448 out of over 22,000 transcripts were
differentially expressed. Under these conditions, there were 172
transcripts with increased expression in the sik1
flp/flp ES cells, while
Figure 3. sik1 deficiency affects terminal cardiogenic differentiation. (A) Q-PCR of a pluripotency gene (Oct3/4), of an early mesodermal
marker (brachyury), of pre-cardiac mesodermal markers (mesp1, mesp2, Isl1), early cardiogenic markers (Mef2c, Tbx5, Nkx2.5) and terminal cardiac
markers (a-MyHC, Mlc2V, aCach and cTnI) during in vitro differentiation of wild-type and sik1
flpflp ES cells. (B) Q-PCR on hematopoietic/endothelial
markers (runx1, vegfC and flk1). n=3, *, P,0.05, **, P,0.001 vs. control cells. P values were calculated using a two-tailed, unpaired t test.
doi:10.1371/journal.pone.0009029.g003
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identify the biological processes in which the genes transcriptionally
affected in sik1
flp/flp ES cells are involved, we performed a Gene
Ontology analysis. The analysis revealed a significant enrichment in
different GOBiological Process categories, such as ‘‘steroid metabolic
process’’, ‘‘calcium ion transport’’, ‘‘ion transport’’ and ‘‘di-, tri-valent
inorganic cation transport’’ (Table S3) in which sik1 is already known
to be involved [16,22]. This observation suggests that sik1 deficiency
has an effect on the transcriptomein ES cells,whichisconsistent with
the data obtained.
Sik1 is known to regulate transcription through inhibitory
phosphorylation of a family of CREB coactivators, called
TORCs/CRTCs, and that down-regulation of sik1 would be
expected to increase the expression of CREB target genes [23] As
furtheranalysis,wedecided toinvestigatewhethergenesfoundtobe
differentially expressed in the sik1
flp/flp ES cells could be under the
regulation of transcriptional factors belonging to the CREB family.
Interestingly, Table S4 shows that CREB transcription binding
sites are found to be over-represented in upregulated genes, while
they are clearly under-represented in the downregulated genes.
Given these data, which provide additional evidence of sik1
deficiency activity in our cells, we further analyzed the data
obtained by array experiments using two stringent criteria: 1.
looking for genes expressed in the heart; 2. looking for genes
already known to cause cardiac phenotype when mutated (i.e.
knock-out models). Using the MGI (mouse genome informatics)
database, we identified 68 genes (42 downregulated and 26
upregulated) among the transcriptionally affected genes (Table
S5). Interestingly, one of the most downregulated genes expressed
in the heart is cdkn1c (22.75 (log2); p-value, 1.11E-16). Cdkn1c gene
codifies for the p57 protein belonging to the family of KIP/CIP
factors that are cyclin-dependent kinase inhibitors (CDKI)
involved in cell cycle arrest.
Sik1 Regulates p57kip2 Only in the Cardiogenic Program
It is worth noting here that the levels of p57
Kip2 are very low in
proliferating cells and differentiation signals result in its accumu-
lation, which is necessary to withdraw cells from the cell cycle and
to move them toward differentiation [7]. Given that p57
Kip2 is
involved in regulating the cell cycle, it is possible to reason that it
Figure 4. Measurement of myosin positive cells in wild-type and sik1
flp/flp EBs by FACS. (A) EBs were analyzed by FACS at days 0, 5, 6, 7, 9,
11 and 12 of differentiation with the antibody MF20. Data represent results of one out of three independent experiments. (B) Graphic representation
of FACS analysis. Data represent mean 6 S.E. of three biologically independent experiments (*, p,0.05 compared with wild-type EBs. P-values were
calculated using a two-tailed, unpaired t test). (C) Graphic representation of low fluorescence vs high fluorescence MF20 positive cells distribution, as
by FACS analysis (n=3). Wild-type and sik1
flpflp cells were used throughout the analysis. (D) Costaining experiment using anti-troponin and anti-BrdU
to detect proliferating cells only in cardiomyocytes population.
doi:10.1371/journal.pone.0009029.g004
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cardiomyocyte differentiation.
In order to visualize the temporal regulation of p57
Kip2
throughout the differentiation process, we first evaluated the
transcript levels of Cdkn1c gene in undifferentiated ES cells, in
differentiating EBs and in fully differentiated cardiomyocytes, in
both the wild-type and sik1
flp/flp cells. We also investigated the
expression levels of the two other members of the KIP family,
Cdkn1a (p21) and Cdkn1b (p27), during cardiomyocyte differenti-
ation. As shown in figure 6A, p57
Kip2 was expressed at very low
levels in undifferentiated wild-type ES cells and in day 1–5
differentiating EBs. From day 5 onward, p57
Kip2 expression
increased, and its expression correlated to the appearance of
beating EBs. It is thus tempting to hypothesize that p57
Kip2 is
upregulated to progressively withdraw cells from the cell cycle and
direct them toward differentiation. In sik1
flp/flp cells, the expression
levels of p57
Kip2 were strongly downregulated throughout
differentiation, being barely detectable (Fig. 6A). The levels of
the two other members of the KIP family, p21 and p27, in the
sik1
flp/flp cells were comparable to those seen in wild-type cells,
although a reduction in p21 was observed (Fig. 6A). We confirmed
these results using Western immunoblotting (Fig. 6B). As shown by
the relative quantitative analysis (Fig. 6C), the protein levels were
in accordance with the mRNA levels.
To further prove the specific effect of sik1 deficiency in the
cardiogenic program, we measured the temporal expression of
p57
Kip2 throughout neuronal differentiation of both wild-type and
sik1
flp/flp ES cells. As opposed to what we observed in cardiac
differentiation, the temporal regulation of cdkn1c gene was not
affected throughout the neuronal differentiation in sik1
flp/flp
population (Fig. 6D). These results are in line with our previous
data showing that sik1 deficiency does not affect neuronal
differentiation (Fig. 5).
Sik1 Directly Regulates p57
Kip2
p57
Kip2 and other CDKIs have pivotal roles in the regulation of
the transition between cell cycle and terminal differentiation in
many cell types [24].
To prove that downregulation of p57
Kip2 directly affect the
cardiogenic program, we evaluated whether re- expression of
p57
Kip2 in sik1
flp/flp cells might rescue the cardiogenic defect of
these cells.
To this end, we generated transgenic sik1
flp/flp cells over-
expressing p57
Kip2. After selection of positive clones both by PCR
(data not shown) and by western blot (Fig. 7A), we evaluated the
effects of the p57
Kip2 over-expression on cardiac differentiation.
Remarkably, the over-expression of p57
Kip2 in sik1
flp/flp cells was
able to fully rescue the cardiac phenotype, as shown by FACS and
qPCR analysis. Upon forced expression of p57 the number of
cardiomyocytes (MF-20 positive cells) significantly increased in the
crucial time window (d5–d7) in sik1
flp/flp-derived EBs (Fig. 7B).
Expression data supported the FACS analysis (Fig. 7C), demon-
strating that p57
Kip2 over-expression has the ability to fully rescue
the delayed phenotype observed in the sik1
flp/flp cells.
Altogether, these findings demonstrated that sik1 regulated
cardiomyocytes development via the p57
Kip2 signaling.
Figure 5. Neuronal differentiation of wild-type and sik1
flp/flp ES cells. (A) Immunofluorescence analysis of wild-type and sik1
flp/flp EBs at day
16 of differentiation using an anti-bIII-tubulin antibody reveals the presence of neurons. (B) Quantitative real-time PCR analysis to measure the
expression of the neuron- and glial-specific markers NFM and GFAP, respectively, in wild-type and sik1
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Sik1 (also known as SNF1LK, sucrose nonfermented 1-like kinase)
encodes a serine/threonine kinase that belongs to a family of
AMP-activated protein kinases (AMPK) involved in the regulation
of metabolism during energy stress [25].
The expression pattern of sik1 during embryogenesis suggests its
involvement in cardiomyocyte differentiation and/or heart
development. However, despite the significant research efforts
toward the comprehension of the function of such a protein, the
definition of its biological significance during cardiac development
is still unknown.
We decided to investigate the role of sik1 gene during cardiac
differentiation using a gene trap ES cell line and revealed a
novel role of sik1 in controlling the cell cycle progression of
cardiomyoblasts.
Using the ES/EB model, we found that the absence of sik1
produced a consistent delay of terminal cardiac differentiation and
most remarkably, that this delay can be explained with the failure
of the transcriptional regulation of the cyclin-dependent kinase
inhibitor p57
Kip2. It is worth noting here that the levels of p57
Kip2
are very low in proliferating cells, and that differentiative signals
result in its accumulation, which is necessary to withdraw cells
from the cell cycle and to move them toward differentiation [8].
These data are in agreement with our observation that, during
cardiac differentiation, the expression of p57
Kip2 increases with the
appearance of cardiomyocytes. Given that sik1 deficiency
completely suppressed the expression of p57
Kip2, we speculated
that defective signalling in the cell-cycle exit of these cells causes
the delayed phenotype. The findings presented in this study
indicate that sik1 signaling contributes to the cardiogenic program
through the coordinated action of p57
Kip2. Moreover, p57
Kip2
over-expression experiment indicates that p57
Kip2 is a downstream
mediator of sik1, acting specifically in the cardiac differentiation
process.
It is worth noting that the absence of cdkn1c transcriptional
activation during differentiation of sik1
flp/flp ES cells does not
prevent the formation of mature cardiomyocytes. This might be
Figure 6. Expression profile of CDKIs during both cardiomyocyte and neuron differentiation. (A) Expression profile of genes encoding
for CDK inhibitors belonging to the KIP/CIP family (Cdkn1a, Cdkn1b and Cdkn1c) measured by quantitative real-time PCR at different time points
during cardiomyocyte differentiation of wild-type and sik1
flpflp ES cells, n=3, *, P,0.05, **, P,0.001 vs. control cells. P values were calculated using a
two-tailed, unpaired t test. (B) Western blots analysis of CDKIs protein level during in vitro cardiomyocyte differentiation of wild-type and sik1
flpflp ES
cells. (C) p21, p27 and p57 protein levels were expressed as the ratio between their arbitrary densitometric units (ADU) and b-actin. Densitometry
analyses were performed using the ImageQuant 5.2 software (GE Healthcare). (D) Expression profile of Cdkn1c gene measured by quantitative real-
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family, as p21 and p27, that is not abolished during differentiation
and which can likely compensate for the lack of cdkn1c. In addition,
our results show that sik1 specifically regulates the appearance of
cardiac cells, since the timing of appearance of neurons is not
affected by sik1 deficiency. Our findings clearly shown that sik1 is
one of the regulators in the cascade of events leading to
cardiomyogenesis through the modulation of p57
Kip2 expression.
Notably, the balance between proliferation and terminal
differentiation is a critical point in organ development [26],
especially for the heart that is the first organ to form in the embryo
[27]. Indeed, cardiac growth and chamber maturation are
regulated by temporally and spatially controlled processes,
resulting in a precise regulation of cell cycle exit and cell
differentiation of cardiac cells. The ability of these cells to undergo
cell division decreases progressively during heart development,
such that adult myocytes cannot divide [7]. In this respect, cell
cycle regulatory proteins are essential in orchestrating this process.
Although the identities of signals involved in cardiac specifica-
tion are far to be fully elucidated, p57
Kip2 is one of the intracellular
candidates initially expressed in the myocardium at E10.5 [8].
Embryos lacking p57
Kip2 exhibit hyperplasia in several organs and
delayed differentiation, probably due to failure to exit from the cell
cycle in a timely fashion. Surprisingly, cardiac defects have not
been reported in p57
Kip2 deficient mice [28], suggesting that other
regulators are likely to be involved in a cooperative way with
p57
Kip2 in the cardiac cell cycle withdrawal and terminal
differentiation. The gene profiling study performed on sik1
deficient ES cells revealed that some of the transcriptional affected
genes are expressed in the heart or involved in cardiac defects.
This data suggests that sik1 provide a critical growth signal for
cardiomyoblasts, acting not only on cdkn1c gene, to promote cell
cycle exit, but also on other genes involved in cardiomyocyte
differentiation and/or heart development.
The observation that sik1 plays an important role in muscle
function as HDAC5 kinase raises interesting questions regarding
the possible link between HDAC5 and cell cycle in ES cells.
HDAC5 belongs to class II HDAC enzymes and is highly enriched
in muscles, heart and brain, as HDAC9 [29]. Although transgenic
mice lacking either HDAC5 or HDAC9 are viable, mice lacking
both HDAC5 and 9 show a propensity for lethal ventricular septal
defects and thin-walled myocardium, which tipically arise from
abnormalities in growth and maturation of cardiomyocytes [30].
The development of cardiac defects in these double KO mice
probably results from a precocious differentiation and cell cycle
withdrawal of cardiomyocytes, causing hypocellularity of the
myocardium. Is sik1 involved in this intrigued mechanism? Our
results shed light on the role of sik1 in cardiomyogenesis and,
although further investigation is required to solve this issue, our
data provide a new piece of puzzle in the understanding of the
molecular mechanisms regulating cardiomyocyte cell cycle, which
is of vital importance for future clinical approach.
To our knowledge, our manuscript provides the first evi-
dence that sik1 via p57
Kip2 plays a central role in the time
clock mechanism that regulates cardiac cell proliferation and
differentiation.
Figure 7. Over-expression of p57 in sik1
flp/fl cells. (A) Western blot analysis with the anti-p57 antibodies to detect the expression of transgene
in three different clones in sik1
flpflp ES cells. (B) Measurement of myosin positive cells in wild-type, sik1
flp/flp and sik1
flp/flp overexpressing p57 EBs by
FACS, analyzed at days 0, 5, 6 and 7 of differentiation with the antibody MF20. Data represent results of one out of two independent experiments (C)
Q-PCR analysis of terminal cardiac markers (a-MyHC, Mlc2V, aCach and cTnI).
doi:10.1371/journal.pone.0009029.g007
Sik1 Controls Cardiomyogenesis
PLoS ONE | www.plosone.org 9 February 2010 | Volume 5 | Issue 2 | e9029Worth noting, mouse sik1 maps on mouse chromosome 17 in a
region that is syntenic with human chromosome 21q22.3, where
the human ortholog is located. It is well known that trisomy of 21
leads to Down syndrome, the most common genetic cause of
mental retardation in the human population. Notably, forty
percent of newborns with Down syndrome have congenital heart
defects (CHD), of which the most frequent are atrioventricular
septal defects [31]. Molecular studies of rare individuals with
CHDs and partial duplications of chromosome 21 have estab-
lished a candidate region of 5 Mb in which SIK is localized [32].
Given that sik1 is specifically involved in cardiomyogenesis, we can
speculate that this gene can play a role in CHDs observed in
Down syndrome patients, opening new avenues in the under-




The experiments with murine cell lines were performed in
compliance with the institutional guidelines (Italian Legislative
Decree Nu 120/92 (published on February 18th 1992) being the
official Italian publication of the European Directive Nu 88/320/
CEE and 90/18/CEE concerning matters of inspections and
verifications of Good Laboratory Practices). The parental cell line
E14Tg2a.4 was obtained by Baygenomics, previously described in
Brennan J, Skarnes WC. [33]. The generation of sik1wt/flp cell
line was described in Cobellis, G et al. [14] and the sik1
flp/flp and
HAsik1 cell lines were obtained by further modifications of sik1
+/flp
cell line described in this report
Plasmids
rSik1 coding was obtained digesting the plasmid pGFPC-rSik1
BamHI/EcoRI and cloned into the expression vector
pcDNA3X(+)HA (Sigma-Aldrich). The sik1 fragment encoding the
amino acids 1–249 was amplified from ES cells cDNA with the primers
sik1HAfor 59-CTCGAGATGGTGATCATGTCGGAGT-39 and
sik1HArev 59-TCTAGATCACTAAGGGTTCTTCTTCTTTGG-
T-39 containing the XhoI and XbaI sites, respectively. The PCR
product was subcloned in pCR-Blunt II-TOPO vector (Invitrogen),
digested XhoI/XbaI from the TOPO Blunt II and cloned into
pcDNA3X(+)HA.
The plasmid pGFPC-rSik1 was a kind gift of Dr. Hiroshi
Takemori.
Cell Culture




flp/flp + HAsik1) were grown in
DMEM supplemented with 15% (vol vol) fetal bovin serum,
2 mM L-glutamine, 1 mM MEM sodium pyruvate, 0.1 mM 2-
mercaptoethanol (all from Invitrogen), 1,000 units/ml leukemia
inhibitory factor (Esgro, Chemicon). HEK293T cells were
maintained in DMEM (Invitrogen) containing 10% of fetal bovine
serum (Hyclone).
Production and Identification of Homozygous Mutant ES
Cells
In order to obtain homozygous sik1
flp/flp ES cells, heterozygous
sik1
wt/flp ES cells were cultured in increasingconcentrations of G418
(2 and 3 mg/ml) for 14 days as previously described [15]. After the
selection, to identify homozygous sik1
flp/flp ES cells, 96 surviving
clones were analyzed by RT-PCR using the following primers:
sik1UP (59-TCGGTGTGGTGCTGTACGT-39), sik1LW (59-AC-
TGCTGGGGGAGATGGAT-39) and L232 (59-GATGTGCTG-
CAAGGCGATTA-39), as depicted in figure 1.
Production of sik1
flp/flp + HAsik1 and p57 ES Cells
The sik1
flp/flp ES cell line was electroporated with 4 mg plasmid
vector Pallino b-actin using the Nucleofector II (Amaxa biosys-
tem). This plasmid vector contains the HAsik1 cDNA, driven by
the b-actin promoter, and the puromycin resistance gene, driven
by the phospho-glycerokinase promoter. The plasmid used to
introduce p57 contains the p57 cDNA driven by PGK promoter.
The stable selection marker is puromycin. In order to identify
HAsik1 or p57 overexpressing ES cells, two weeks after selection
with 1.2 mg/mL puromycin, the resistant colonies were screened
by RT-PCR using the primers sik1UP and sik1LW for HAsik1
clones and with vector up and p57low for the p57 clones.
ES Cells Differentiation
ES cells were differentiated by EB formation using the ‘‘hanging
drop’’ method as previously described [13,34]. The cardiomyocyte
differentiation medium consists of the ES cells medium depleted of
LIF. The neuronal and glial differentiation medium consists of the
Knockout medium (Invitrogen) supplemented with 15% Knockout
Serum SR, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM
2-mercaptoethanol (all from Invitrogen) and depleted of LIF.
Cell Proliferation Assay
Wild type and sik1
flp/flp ES cells (5610
4 cells) were subjected to a
pulse with 5-bromo-29-deoxyuridine (BrdU) (Sigma, UK) for
14 hours at 37uC in gelatinized Chamber slide (Nunc) After that,
the cells were washed with PBS (Invitrogen) then fixed for 10
minutes in 4% paraformaldehyde. The fixed cells were incubated
with 50 mM Glycine and then permibilized with 50 mM NaOH
for 10 seconds, washed in PBS and blocked in 5% goat serum/
0,1% NP-40/PBS for 30 minutes at room temperature. BrdU
incorporation into DNA was detected with a monoclonal antibody
anti BrdU G3–G4 (Sigma-Aldrich) diluted 1:500 at room
temperature for 1 hour. Goat-anti mouse conjugated with FITC
(Amersham) was used as secondary antiboby for immunofluores-
cence detection. Nuclei were counterstaining with DAPI and
visualized with a fluorescent microscope. Images were taken with a
digital camera (Zeiss Axiocam 130061030 pixel) mounted on a
Axioplan 2 microscope (Carl Zeiss Inc.) with 60x NA 1.40
objectives (Carl Zeiss Inc.) at room temperature using AxioVision
software (Carl Zeiss Inc.).
Cell Cycle Analysis
Cellular DNA content was determined by staining cells with
propidium iodide and analyzed them on a FACS instrument
(Becton-Dickinson). ES cells were trypsinized, washed with PBS
and resuspended in 500 ml of staining solution containing Na-
citrate 0,1% (p/v), Nonidet P-40 0,1% (v/v), 10 mg/ml RNase and
propidium iodide 50 mg/ml for 30 minutes. Cells were analyzed
by FACS, and the proportion of cells in G0/G1, S, and G2/M
phases was estimated by the Modfit cell-cycle analysis software.
FACS Analysis
Flow cytometry was performed according to Hao J et al. [35].
Briefly, EBs were dissociated into single cell suspensions after
trypsinization (2610
6 cells). Following a wash with 10%FBS/
DMEM, cells were permeabilized with 0.05% saponin/PBS buffer
for 20 minutes on ice. Cells were then stained with an antibody
against sarcomeric myosin (MF-20 or cTnT antibodies, both from
Hybridoma bank; dilution 1:100 in 10%FBS/DMEM) for 1 hour.
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with an anti-mouse secondary antibody conjugated to FITC
(dilution 1:100 in 10%FBS/DMEM) for 30 minutes in the dark.
After additional washes (2x) in 10%FBS/DMEM, cells were
resuspended in 500 ml 10%FBS/DMEM and analyzed on the
FACS instrument (Becton-Dickinson).
The costaining with anti-BrdU-PE antibody was performed
incubating the cells with bromodeoxiuridine (Roche) for 6 hr.
After that, we proceeded with the anti-cTnI staining as previously
described; then, cells were fixed with Cytofix-Perm solution
(Becton Dickinson) for 209 on ice and treated with DNAseI
(Quiagen) to expose the DNA (1 hr at 37uC). Treated cells were
incubated with anti-BrdU-PE (BD) for 309 in the dark and
analyzed on cytofluoremeter after extensive washes.
The number of labeled cells were determined with a
FACSCalibur and analyzed by FlowJo software.
Immunofluorescence
HEK293T cells were cultured on chamber slides (Lab-Tek II
Chamber Slide w/Cover RS Glass Slide Sterile, Nunc) and
transfected with the vectors pcDNA3X (+) HA-sik1 (1–249) and
pcDNA3X (+) HA-rSik1 using the PolyFect Transfection Reagent
(Qiagen). After 48 hours of transfection, cells were washed with
PBS (Invitrogen), and fixed for 10 minutes in 4% paraformalde-
hyde. After extensive washing in PBS, the fixed cells were
incubated with 10% of Bovine Serum Albumin and 0.1% Tween
20 diluted in PBS (Invitrogen) for 1 hour at room temperature,
and then incubated with an anti-HA antibody (dilution 1:250;
Sigma-Aldrich) for 2 hours at room temperature. After extensive
washing, the antigen-antibody complexes were visualized with
anti-rabbit IgG-FITC conjugate IgG (dilution 1:100; Amersham
Biosciences) for 1 hour at room temperature. Nuclei were
counterstained with DAPI. EB-derived neurons were plated into
gelatin-coated 100 mm dishes (Nunc), washed with PBS (Invitro-
gen) and fixed for 10 minutes in 4% paraformaldehyde. The fixed
EBs were incubated with 10% of Normal Goat Serum (Dako), 1%
of Bovine Serum Albumine, 0.1% Triton X-100 diluted in PBS for
30 minutes at room temperature, and then reacted with an anti-
bIII tubulin antibody (dilution 1:400; Sigma-Aldrich) for 2 hours
at room temperature. The antigen-antibody complexes were
visualized with rabbit anti-mouse IgG-FITC conjugate IgG
(dilution 1:35; Dako) for 1 hour at room temperature. Nuclei
were counterstained with DAPI. Images were taken through a
digital camera (Zeiss Axiocam 130061030 pixel) mounted on an
Axioplan 2 microscope (Carl Zeiss) with a 60x NA 1.40 lens (Carl
Zeiss) at room temperature using AxioVision software (Carl Zeiss).
For MF20 experiment, the fixation was performed with methanol:
acetone (7:3).
Immunoprecipitation and Kinase Assay
Cells (2610
6) plated on a 10-cm dish were transformed with
6 mg of expression plasmids for FLAG-tagged wild type and
mutant sik1 by using 20 ml of LipofectAMINE 2000 (Invitrogen).
After 36 h of incubation, cells were lysed in 0.7 ml of lysis buffer.
The FLAG-tagged sik proteins were immunoprecipitated with an
anti- FLAG M2 affinity Gel (SIGMA). Aliquots of purified
FLAG-SIK1 were then subjected to western blot analyses with
the anti-FLAG-HRP antibodies and to in vitro kinase assays.
Purified SIKs were incubated in 40 mM MOPS/NaOH pH 7.0,
1 mM EDTA with 0.1 mM of AMARA substrate (Enzo Life
Sciences) in the presence of 25 mM MgAc and 0.5 mCi
(18.5 kBq) of [c-32P]-ATP at 30uC for 30 min. The kinase
reaction was stopped by adding 5 ml of 3% phosphoric acid. An
aliquot was transferred to P81 filters (Whatman) and after
extensive washes in 75 mM phosphoric acid read in a scintillation
counter.
RNA Preparation, RT-PCR and Q-PCR
Total RNAs from either undifferentiated ES cells or
differentiating EBs were extracted using RNeasy Miny Kit
(Qiagen). First strand cDNA was synthesized from 1 mgo ft o t a l
RNA using QuantiTect Reverse Transcription kit (Qiagen). RT-
PCR was performed on cDNA synthesized from wild-type and
sik1
flp/flp + HAsik1 ES cells using LA-TAQ (TAKARA). sik1UP
and sik1LW primers were used to amplify the sik1 transcript and
GAPDH as an internal control. Amplification products were
analyzed on ethidium bromide-stained 1% agarose gels and
visualized at Gel Doc 2000 (Bio-Rad) using Quantity One
software. Q-PCR was performed on the Light Cycler 480 real-
time PCR system (ROCHE) using SYBR Green (Light Cycler
480 SYBR Green I master, ROCHE). Each sample was
amplified in triplicate. The primers used are available on
request.
Microarray Hybridization and Analysis
Transcriptome analysis was performed comparing total RNA
extracted from wild-type and mutant homozygous ES cells. The
labeling of the RNAs, the hybridization on Affymetrix GeneChip
MOE 430A 2.0 and analysis were performed by the Boston
University Microarray Resource. The array data analysis was
performed using the RMA algorithm.
The array experiments were submitted to MIAMEXPRESS
and the assigned accession number is E-MEXP-1646.
Detection of Functional DNA Motifs
The following bioinformatics approach was used to detect the
presence of eventual functional DNA motifs regulating the
expression of the genes found to be differentially expressed.
Affymetrix probeset IDs were used to retrieve a list of
corresponding Ensembl transcript IDs from the Ensembl database
(release 56, based on Mus Musculus NCBIM37). Transcript
identifiers were then used to obtain sequences located within 1 kb
upstream of each transcription strating site (TSS) (http://rsat.
scmbb.ulb.ac.be/rsat/). Sequences were masked for the presence
of repeats and coding sequences, as well as redundant sequences
due to alternative transcripts were also avoided.
S e q u e n c e so b t a i n e dw e r ef i n a l l ys c a n n e df o rt h ep r e s e n c eo f
specific functional DNA motifs by using the Clover algorithm
and the library of motifs provided by TRANSFACH Profes-
sional 2009.2. For each sequence in both datasets, a P value
was estimated as probability of obtaining a raw score of same
size or greater merely by chance, using a shuffled version of the
target sequence as control and a very stringent pvalue cut-off of
0.001.
Western Blotting Analysis
ES cells and EB lysates were prepared in RIPA lysis buffer,
separated by 10% SDS/PAGE and transferred onto PVDF
membranes. Western blots were performed using antibodies
against b-Galactosidase (dilution 1:2000; Chemicon), p21 (dilution
1:200; Abcam), p27 (M-197) (dilution 1:200; Santa Cruz), p57 (H-
91) (dilution 1:200; Santa Cruz) and actin (dilution 1:10000;
Sigma-Aldrich). Detection of proteins was accomplished using
Horseradish-peroxidase-conjugated secondary antibodies and
enhanced chemioluminescence (ECL) purchased from Amersham.
Scanning densitometry was performed using the ImageQuant
software (Molecular Dynamics).
Sik1 Controls Cardiomyogenesis
PLoS ONE | www.plosone.org 11 February 2010 | Volume 5 | Issue 2 | e9029Supporting Information
Table S1 Genes up-regulated in sik1
flp/flp ES cells, FDR,5%.
Found at: doi:10.1371/journal.pone.0009029.s001 (0.06 MB
XLS)
Table S2 Genes down-regulated in sik1
flp/flp ES cells, FDR,5%.
Found at: doi:10.1371/journal.pone.0009029.s002 (0.07 MB
XLS)
Table S3 Gene Ontology analysis on the gene-set transcription-
ally affected in sik1
flp/flp ES cells.
Found at: doi:10.1371/journal.pone.0009029.s003 (0.04 MB
DOC)
Table S4 Detection of functional DNA binding sites on genes
differentially expressed between wt and sik1
flp/flp ES.
Found at: doi:10.1371/journal.pone.0009029.s004 (0.02 MB
XLS)
Table S5 Transcriptionally affected genes by sik1 deficency
expressed in heart or causing cardiac defects.
Found at: doi:10.1371/journal.pone.0009029.s005 (0.12 MB
DOC)
Acknowledgments
We thank Diego Di Bernardo and Luisa Cutillo for array analysis; Giorgio
Russolillo for the statistical analysis; Marco Sardiello, Diego Medina,
Alessandro Fraldi, Caterina Missero and Pia Cosma for critical reading of
the manuscript. We also thank Dr Hiroshi Takemori, who provides the
plasmid pGFPC-rSik1. We also thank past and present members of Prof.
Ballabio’s lab.
Author Contributions
Conceived and designed the experiments: AR EL GC. Performed the
experiments: AR EL. Analyzed the data: AR EL GM AB GC. Contributed
reagents/materials/analysis tools: GR. Wrote the paper: AR GM GC.
Financial support: GM AB. Final approval of manuscript: GM AB.
References
1. Srivastava D, Olson EN (2000) A genetic blueprint for cardiac development.
Nature 407: 221–226.
2. Lints TJ, Parsons LM, Hartley L, Lyons I, Harvey RP (1993) Nkx-2.5: a novel
murine homeobox gene expressed in early heart progenitor cells and their
myogenic descendants. Development 119: 969.
3. Asakura A, Lyons GE, Tapscott SJ (1995) The regulation of MyoD gene
expression: conserved elements mediate expression in embryonic axial muscle.
Dev Biol 171: 386–398.
4. Griffin KJ, Stoller J, Gibson M, Chen S, Yelon D, et al. (2000) A conserved role
for H15-related T-box transcription factors in zebrafish and Drosophila heart
formation. Dev Biol 218: 235–247.
5. Srivastava D, Cserjesi P, Olson EN (1995) A subclass of bHLH proteins required
for cardiac morphogenesis. Science 270: 1995–1999.
6. McKinsey TA, Zhang CL, Olson EN (2002) MEF2: a calcium-dependent
regulator of cell division, differentiation and death. Trends Biochem Sci 27:
40–47.
7. Brooks G (2005) Cyclins, cyclin-dependent kinases, and cyclin-dependent kinase
inhibitors: detection methods and activity measurements. Methods Mol Biol 296:
291–298.
8. Kochilas LK, Li J, Jin F, Buck CA, Epstein JA (1999) p57Kip2 expression is
enhanced during mid-cardiac murine development and is restricted to trabecular
myocardium. Pediatr Res 45: 635–642.
9. Ruiz JC, Conlon FL, Robertson EJ (1994) Identification of novel protein kinases
expressed in the myocardium of the developing mouse heart. Mech Dev 48:
153–164.
10. Stephenson A, Huang GY, Nguyen NT, Reuter S, McBride JL, ey al (2004)
snf1lk encodes a protein kinase that may function in cell cycle regulation.
Genomics 83: 1105–1115.
11. van der Linden AM, Nolan KM, Sengupta P (2007) KIN-29 SIK regulates
chemoreceptor gene expression via an MEF2 transcription factor and a class II
HDAC. Embo J 26: 358–370.
12. Berdeaux R, Goebel N, Banaszynski L, Takemori H, Wandless T, et al. (2007)
SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. Nat
Med 13: 597–603.
13. Wobus AM, Guan K, Yang HT, Boheler KR (2002) Embryonic stem cells as a
model to study cardiac, skeletal muscle, and vascular smooth muscle cell
differentiation. Methods Mol Biol 185: 127–156.
14. Cobellis G, Nicolaus G, Iovino M, Romito A, Marra E, et al. (2005) Tagging
genes with cassette-exchange sites. Nucleic Acids Res 33: e44.
15. Mortensen RM, Conner DA, Chao S, Geisterfer-Lowrance AA, Seidman JG
(1992) Production of homozygous mutant ES cells with a single targeting
construct. Mol Cell Biol 12: 2391–2395.
16. Katoh Y, Takemori H, Horike N, Doi J, Muraoka M, et al. (2004) Salt-inducible
kinase (SIK) isoforms: their involvement in steroidogenesis and adipogenesis.
Mol Cell Endocrinol 217: 109–112.
17. Zeineddine D, Papadimou E, Chebli K, Gineste M, Liu J, et al. (2006) Oct-3/4
dose dependently regulates specification of embryonic stem cells toward a
cardiac lineage and early heart development. Dev Cell 11: 535–546.
18. Liu Y, Asakura M, Inoue H, Nakamura T, Sano M, et al. (2007) Sox17 is
essential for the specification of cardiac mesoderm in embryonic stem cells. Proc
Natl Acad Sci U S A 104: 3859–3864.
19. Sepulveda JL, Belaguli N, Nigam V, Chen CY, Nemer M, et al. (1998) GATA-4
and Nkx-2.5 coactivate Nkx-2 DNA binding targets: role for regulating early
cardiac gene expression. Mol Cell Biol 18: 3405–3415.
20. Grepin C, Nemer G, Nemer M (1997) Enhanced cardiogenesis in embryonic
stem cells overexpressing the GATA-4 transcription factor. Development 124:
2387–2395.
21. Politis PK, Thomaidou D, Matsas R (2008) Coordination of cell cycle exit and
differentiation of neuronal progenitors. Cell Cycle 7: 691–697.
22. Sjostrom M, Stenstrom K, Eneling K, Zwiller J, Katz AI, et al. (2007) SIK1 is
part of a cell sodium-sensing network that regulates active sodium transport
through a calcium-dependent process. Proc Natl Acad Sci U S A 104:
16922–16927.
23. Katoh Y, Takemori H, Lin X, Tamura M, Muraoka M, et al. (2006) Silencing
the constitutive active transcription factor CREB by the LKB1-SIK signaling
cascade. FEBS J 273: 2730–2748.
24. Gui H, Li S, Matise MP (2007) A cell-autonomous requirement for Cip/Kip
cyclin-kinase inhibitors in regulating neuronal cell cycle exit but not
differentiation in the developing spinal cord. Dev Biol 301: 14–26.
25. Hardie DG, Carling D (1997) The AMP-activated protein kinase–fuel gauge of
the mammalian cell? Eur J Biochem 246: 259–273.
26. Buttitta LA, Edgar BA (2007) Mechanisms controlling cell cycle exit upon
terminal differentiation. Curr Opin Cell Biol 19: 697–704.
27. Olson EN (2004) A decade of discoveries in cardiac biology. Nat Med 10:
467–474.
28. Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, et al. (1997) Altered cell
differentiation and proliferation in mice lacking p57KIP2 indicates a role in
Beckwith-Wiedemann syndrome. Nature 387: 151–158.
29. Haberland M, Montgomery RL, Olson EN (2009) The many roles of histone
deacetylases in development and physiology:implications for disease and
therapy. Nat Rev Genet 10: 32–42.
30. Chang S, et al. (2004) Histone deacetylases 5 and 9 govern responsiveness of the
heart to a subset of stress signals and play redundant roles in heart development.
Mol Cell Biol 24: 8467–8476.
31. Antonarakis SE, Lyle R, Dermitzakis ET, Reymond A, Deutsch S (2004)
Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat
Rev Genet 5: 725–738.
32. Barlow GM, Chen XN, Shi ZY, Lyons GE, Kurnit DM, et al. (2001) Down
syndrome congenital heart disease: a narrowed region and a candidate gene.
Genet Med 3: 91–101.
33. Brennan J, Skarnes WC (1999) Gene trapping in mouse embryonic stem cells.
Methods Mol Biol 97: 123–38.
34. Wobus AM, Boheler KR (2005) Embryonic stem cells: prospects for
developmental biology and cell therapy. Physiol Rev 85: 635–678.
35. Hao J, Daleo MA, Murphy CK, et al. (2008) Dorsomorphin, a selective small
molecule inhibitor of BMP signaling, promotes cardiomyogenesis in embryonic
stem cells. PLoS ONE Aug 6 3(8): e2904.
Sik1 Controls Cardiomyogenesis
PLoS ONE | www.plosone.org 12 February 2010 | Volume 5 | Issue 2 | e9029